Beyond Inhibition: The Shift Toward Total Protein Elimination
For decades, the gold standard of drug discovery has been inhibition. The goal was simple: find a protein causing disease and block its activity. However, this approach has a fundamental flaw—it leaves the disease-causing protein intact, often allowing the cell to find a workaround or develop resistance.
Enter targeted protein degradation (TPD). Instead of merely blocking a protein’s function, TPD harnesses the cell’s own internal quality-control machinery to remove the protein entirely. This is achieved by using degrader molecules to bring a target protein into proximity with an E3 ligase, an enzyme complex that labels the protein for destruction by the proteasome.
This shift from “blocking” to “eliminating” allows researchers to tackle proteins that were previously considered “undruggable,” including those whose structural functions—not just their enzymatic activity—contribute to disease.
The “Backup System” Breakthrough: Dual-Pathway Recruitment
Despite the promise of TPD, a significant vulnerability has persisted: most degraders rely on a single E3 ligase. In the volatile environment of a cancer cell, this is a risk. If a cell undergoes a mutation or adapts to disable that specific pathway, the drug becomes ineffective, leading to treatment resistance.
Recent research published in Nature Chemical Biology has introduced a game-changing solution. Scientists from CeMM, AITHYRA (both institutes of the Austrian Academy of Sciences), and the Centre for Targeted Protein Degradation (CeTPD) discovered that a single small molecule can recruit two independent protein disposal systems simultaneously.
By focusing on SMARCA2/4—the central ATPase subunits of the BAF chromatin remodelling complex frequently implicated in cancer—the team uncovered a mechanism of built-in redundancy. The compound doesn’t just rely on one E3 ligase; it engages two. If one pathway is compromised, the other continues to drive the degradation of the target protein.
Tackling the Challenge of Drug Resistance
Resistance is one of the most formidable obstacles in oncology. Cancer cells are experts at evolving to circumvent drug mechanisms. By distributing the degradation activity across multiple pathways, this dual-ligase strategy makes it significantly harder for cells to escape treatment.
“By enabling a single molecule to engage multiple degradation pathways, we can introduce redundancy into targeted protein degradation,” explains Georg Winter, Life Science Director at AITHYRA and Adjunct Principal Investigator at CeMM. “This could help overcome one of the key limitations of current degrader therapies, namely their susceptibility to resistance.”
The Future of Resilient Medicine: Tuneable Therapy
Perhaps the most exciting aspect of this discovery is that the system is not static. The research demonstrates that the preference for one ligase over another can be shifted through subtle changes in the chemical structure of the compound or genetic changes in the ligases themselves.
This means that ligase recruitment is not only dual but tuneable. Medicinal chemists can now potentially “dial in” the most effective pathway based on the specific genetic profile of a patient’s tumor.
“This is an incredibly important development. The structural detail we have been able to obtain here is remarkable. We can see precisely how this small molecule creates a new molecular handshake between proteins that would not normally interact. Because we can chemically tune which enzyme is doing the heavy lifting, medicinal chemists have a new avenue to explore when designing the next generation of cancer drugs.” — Professor Alessio Ciulli, Director of the CeTPD
This conceptual framework suggests a future where drugs are designed not just for specificity, but for resilience. The goal is to create medicines that maintain their function even as the biological systems they treat attempt to change.
Frequently Asked Questions
What is the difference between a traditional inhibitor and a protein degrader?
Traditional inhibitors block a protein’s active site to stop it from working, but the protein remains in the cell. Protein degraders mark the protein for complete destruction by the cell’s own disposal system (the proteasome).
Why is “redundancy” important in cancer treatment?
Cancer cells often mutate to survive. If a drug relies on only one pathway to work, a single mutation can render the drug useless. Redundancy (using two pathways) ensures that if one is blocked, the other can still eliminate the target protein.
What are SMARCA2/4 proteins?
They are ATPase subunits of the BAF chromatin remodelling complex. Because they are frequently implicated in the development and progression of cancer, they are prime targets for degradation therapies.
Join the Conversation
Do you believe tuneable, resilient medicines will become the new standard for oncology? We want to hear your thoughts on the future of targeted protein degradation.
Leave a comment below or subscribe to our newsletter for the latest breakthroughs in molecular medicine.
